Prothena Corp. Plc (PRTA)

14.32
0.32 2.19
NASDAQ : Health Technology
Prev Close 14.64
Open 14.65
Day Low/High 14.20 / 14.86
52 Wk Low/High 10.43 / 70.00
Volume 475.08K
Avg Volume 962.00K
Exchange NASDAQ
Shares Outstanding 39.82M
Market Cap 583.39M
EPS -4.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Oversold Conditions For Prothena Corp

Oversold Conditions For Prothena Corp

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Data From Prothena's Ongoing Phase 1/2 Clinical Trial Of NEOD001 In AL Amyloidosis Published In The Journal Of Clinical Oncology

Data From Prothena's Ongoing Phase 1/2 Clinical Trial Of NEOD001 In AL Amyloidosis Published In The Journal Of Clinical Oncology

Interim Results Previously Presented at Meetings of the American Society for Clinical Oncology and the European Hematology Association

Commit To Buy Prothena Corp At $25, Earn 12.3% Annualized Using Options

Commit To Buy Prothena Corp At $25, Earn 12.3% Annualized Using Options

Investors considering a purchase of Prothena Corp plc stock, but tentative about paying the going market price of $41.02/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $25 strike, which has a bid at the time of this writing of $2.00.

Prothena (PRTA) Showing Signs Of A Dead Cat Bounce Today

Prothena (PRTA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

With Martin Shkreli Long Gone, Retrophin is an 'Interesting Opportunity'

Retrophin (RTRX), the biotech company that used to be run by indicted hedge fund manager Martin Shkreki, provides an interesting investment opportunity.

Despite Shkreli Drama, Retrophin Looks Interesting Now

Despite Shkreli Drama, Retrophin Looks Interesting Now

One biotech portfolio manager thinks Retrophin, the biotech company once run by indicted hedge fund manager Martin Shkreli, could be a promising investment.

Prothena (PRTA) Weak On High Volume

Prothena (PRTA) Weak On High Volume

Trade-Ideas LLC identified Prothena (PRTA) as a weak on high relative volume candidate

Perilous Reversal Watch: Prothena (PRTA)

Perilous Reversal Watch: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

Prothena (PRTA) Is Today's Strong On High Volume Stock

Prothena (PRTA) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

Trade-Ideas: Prothena (PRTA) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas: Prothena (PRTA) Is Today's Pre-Market Mover With Heavy Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a pre-market mover with heavy volume candidate

Prothena (PRTA): Today's Weak On High Volume Stock

Prothena (PRTA): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a weak on high relative volume candidate

3 Rising Biotechs That Should Continue Their Upward Trends

3 Rising Biotechs That Should Continue Their Upward Trends

Intra-Cellular Therapies, Prothena and Anacor have solid fundamentals and growth prospects for the new year.

Prothena (PRTA) Highlighted As Today's Perilous Reversal Stock

Prothena (PRTA) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

Today's Dead Cat Bounce Stock Is Prothena (PRTA)

Today's Dead Cat Bounce Stock Is Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Trade-Ideas: Prothena (PRTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Prothena (PRTA) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

New Lifetime High Reached: Prothena (PRTA)

New Lifetime High Reached: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a new lifetime high candidate

Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick

Lilly's Diabetes Drug Makes It a Turner Medical Fund Pick

John Fraunces, portfolio manager for the Turner Medical Sciences Long/Short Fund, said Lilly has merited Wall Street's praise.

Strong On High Relative Volume: Prothena (PRTA)

Strong On High Relative Volume: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a strong on high relative volume candidate

Prothena (PRTA) Highlighted As Today's Perilous Reversal Stock

Prothena (PRTA) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

Perilous Reversal Watch: Prothena (PRTA)

Perilous Reversal Watch: Prothena (PRTA)

Trade-Ideas LLC identified Prothena (PRTA) as a "perilous reversal" (up big yesterday but down big today) candidate

TheStreet Quant Rating: D (Sell)